Myonex Charts Steady Course with Leadership Transition, Eyes Continued Growth in Complex Trials

NEW YORK, NY – November 20, 2025

Myonex, a global provider of clinical trial supply and commercial packaging services, is preparing for a leadership transition, with current CFO Greg Lavin set to succeed James Lovett as CEO on January 1, 2026. Lovett, who is retiring, will remain on the Board of Directors, ensuring continuity during the change. This shift comes at a pivotal time for the company, following several strategic acquisitions and a growing demand for integrated solutions within the increasingly complex landscape of clinical trials.

A History of Strategic Growth

Myonex has undergone a significant transformation in recent years, evolving from a comparator sourcing supplier to a full-service provider catering to the comprehensive needs of pharmaceutical and biotech companies. This evolution has been fueled by strategic acquisitions designed to expand service offerings and geographical reach. The 2022 acquisition of Hubertus Apotheke in Germany, for example, strengthened the company’s capabilities in clinical trial packaging and distribution within the European Union, particularly in supporting decentralized trials. More recently, the acquisitions of SaveWay Compounding Pharmacy and Creapharm Bio & Pharma in 2024 significantly broadened Myonex’s reach into direct-to-patient services and advanced therapy medicinal products (ATMPs), respectively.

“The strategic acquisitions weren’t simply about expanding our footprint; they were about building a truly integrated platform capable of addressing the evolving needs of our clients,” explained an industry source familiar with the company's strategy. “The market is demanding more flexibility, more responsiveness, and more specialized services, particularly as trials become more complex and patient-centric.”

Lavin Poised to Continue Growth Trajectory

Greg Lavin’s appointment as CEO signals a commitment to this established growth trajectory. With over 25 years of experience in finance and accounting within the pharmaceutical services sector, Lavin has been instrumental in Myonex’s transformation during his tenure as CFO. He’s credited with spearheading initiatives in data analytics, IT infrastructure, and strategic acquisitions, laying the groundwork for future success.

“Lavin is a known quantity within the organization, and that’s a significant advantage during this transition,” stated one observer. “He understands the company’s strengths and weaknesses, and he has a clear vision for how to build on the foundation that Lovett established.”

Lavin’s experience extends beyond financial leadership; he has a proven track record of identifying and integrating acquisitions, optimizing operational efficiency, and fostering a culture of innovation. His focus on implementing cutting-edge technologies, such as cloud-based ERP systems and data analytics platforms, positions Myonex to capitalize on emerging trends in the clinical trial supply chain.

Navigating a Complex Market Landscape

The clinical trial supply market is highly competitive, with a mix of large, established players and specialized niche providers. Myonex differentiates itself through its integrated solutions, global reach, and focus on patient-centricity. The company’s ability to provide a comprehensive suite of services, from drug sourcing and packaging to distribution and pharmacy services, streamlines the supply chain and reduces costs for clients.

The demand for more flexible and responsive supply chain solutions is being driven by several factors. The increasing complexity of clinical trial protocols, the growing number of patients participating in trials, and the shift towards decentralized trial models all require a more agile and adaptable approach. Additionally, the rise of personalized medicine and gene therapy is creating demand for specialized supply chain logistics for sensitive and complex biological materials.

“The industry is moving away from a ‘one-size-fits-all’ approach to clinical trial supply,” noted an industry analyst. “Companies need partners who can tailor solutions to their specific needs and challenges, and who can provide the flexibility and responsiveness required to navigate an increasingly complex regulatory environment.”

Myonex’s recent acquisitions have positioned the company to capitalize on these trends. The SaveWay acquisition, for example, enhances its capabilities in direct-to-patient services, allowing it to support decentralized trials and deliver medications directly to patients’ homes. The Creapharm acquisition strengthens its capabilities in advanced therapy medicinal products, a rapidly growing segment of the pharmaceutical market. These strategic investments demonstrate Myonex’s commitment to innovation and its ability to adapt to the evolving needs of the industry.

The future looks promising for the firm as it continues to build on its successes and position itself as a leader in the clinical trial supply market. The firm seems to be well poised for continued innovation and expansion.